Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. (Q48316242)

From Wikidata

Jump to navigation Jump to search

scientific article published on 7 October 2016

Language	Label	Description	Also known as
English	Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.	scientific article published on 7 October 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

inflammatory bowel diseases

0 references

0 references

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Britta Siegmund

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

author name string

A Stallmach

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

C Langbein

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

R Atreya

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

A Dignass

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

K Ende

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

F Hartmann

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

M F Neurath

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

J Maul

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

R Schmelz

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

H Schulze

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

N Teich

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

U von Arnim

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

D C Baumgart

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

C Schmidt

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

language of work or name

0 references

publication date

7 October 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

44

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

11-12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

1199-1212

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Recent trends in the epidemiology of inflammatory bowel diseases: up or down?

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Assessing response and loss of response to biological therapies in IBD.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Loss of response to anti-tumor necrosis factors: what is the next step?

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Vedolizumab as induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

A simple index of Crohn's-disease activity

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Serum Concentration of Anti-TNF Antibodies, Adverse Effects and Quality of Life in Patients with Inflammatory Bowel Disease in Remission on Maintenance Treatment

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn's Disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.13813

21 January 2018

Identifiers

10.1111/APT.13813

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

release_f4y5ixxtfngghndr2p4gzloony

1 reference

https://api.fatcat.wiki/v0/release/f4y5ixxtfngghndr2p4gzloony

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27714831%20AND%20SRC:MED&resulttype=core&format=json

25 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48316242&oldid=1840504659"